C. J. Duncan

Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2

M. Haniffa, G. Reynolds, E. Stephenson, 2021, Nature Communications.

mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals

P. Klenerman, E. Barnes, M. Carroll, 2022, Frontiers in Immunology.

T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study

P. Klenerman, S. Rowland-Jones, M. Haniffa, 2021, The Lancet Microbe.

Type I interferon receptor (IFNAR2) deficiency reveals Zika virus cytopathicity in human macrophages and microglia

S. Cockell, S. Cowley, J. Vowles, 2022, Frontiers in Immunology.

A Novel Case of Homozygous Interferon Alpha/Beta Receptor Alpha Chain (IFNAR1) Deficiency With Hemophagocytic Lymphohistiocytosis

V. Kanderova, E. Froňková, D. Mitra, 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

Human Disease Phenotypes Associated with Loss and Gain of Function Mutations in STAT2: Viral Susceptibility and Type I Interferonopathy

S. Hambleton, C. J. Duncan, C. Duncan, 2021, Journal of Clinical Immunology.

Prior COVID-19 protects against reinfection, even in the absence of detectable antibodies.

B. Payne, T. Planche, A. Breathnach, 2021, The Journal of infection.